Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EBIT (2020 - 2025)

Historic EBIT for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$11.0 million.

  • Insight Molecular Diagnostics' EBIT rose 1825.38% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.3 million, marking a year-over-year decrease of 4065.56%. This contributed to the annual value of -$61.0 million for FY2024, which is 14284.29% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its EBIT stood at -$11.0 million for Q3 2025, which was up 1825.38% from -$9.8 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year EBIT high stood at $5.8 million for Q1 2023, and its period low was -$35.7 million during Q4 2021.
  • In the last 5 years, Insight Molecular Diagnostics' EBIT had a median value of -$9.9 million in 2022 and averaged -$11.2 million.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' EBIT crashed by 46933.14% in 2021, and later soared by 15912.08% in 2023.
  • Insight Molecular Diagnostics' EBIT (Quarter) stood at -$35.7 million in 2021, then surged by 67.35% to -$11.6 million in 2022, then crashed by 38.9% to -$16.2 million in 2023, then plummeted by 107.84% to -$33.6 million in 2024, then surged by 67.15% to -$11.0 million in 2025.
  • Its last three reported values are -$11.0 million in Q3 2025, -$9.8 million for Q2 2025, and -$6.8 million during Q1 2025.